Gertjan Rasschaert

MD, Consultant Gastrointestinal Oncology and Gastroenterology, Universitair Ziekenhuis Leuven | Colon Cancer research at Tejpar lab | @UZLeuven @KU_Leuven

[Anwaar Saeed @AnwaarSaeed3]

🚨 STELLAR-303 makes history! First-ever Ph3 trial to show OS benefit of IO in MSS CRC 🎯
Years of grit & belief led us here 🥹
Endless thanks to Exelixis⁩ for the trust & Dr. Hecht for leading this global win with me! 🎉 ⁦@UPMCHillmanCC⁩ https://t.co/qLG56BiBmc

[Gertjan Rasschaert @GJRas]

Effect of a daily scrum at the GI oncology ward on length of stay: A tertiary center experience

💡 This year, we also have an (online) #ASCO25 abstract in 'Care Delivery and Quality Care'.

🤔 How can we reduce length of stay for our GI onc patients?

@UZLeuven @ASCO

[Gertjan Rasschaert @GJRas]

🧐 Can you predict who’s responding to #BOTBAL and who isn’t? Discover it next week at #ASCO25!

🙋‍♂️ See you on:
Saturday 31st of May, 09:00AM to 12:00PM #CRC poster session, Hall A
Poster Bd 196 - Abstract No 3527

@UZLeuven @KU_Leuven @OmniscopeAI @Agenus_Bio @ASCO

[Gertjan Rasschaert @GJRas]

Looking back at a fruitfull 2 days at the @EORTC GI tract cancer group ‘spring meeting’ that we hosted at @KU_Leuven. The first day was all about academic research collaboration. While today we had a scientific symposium on the #neoadjuvant space in GI cancers.

@FilipHerpe

[Gertjan Rasschaert @GJRas]

⏱️ Timing couldn’t be better. Today I will give a lecture on the growing problem of early onset CRC at the yearly symposium of our residents in internal medicine at @KU_Leuven / @UZLeuven

#EOCRC, @CCAlliance, @FightCRC, @StopDarmkanker, @LKILeuven

[Gertjan Rasschaert @GJRas]

@FilipHerpe and me are happy to invite you to the @EORTC GI Cancer Spring 🌸meeting we are hosting in #Leuven in March. The 2nd day we have a scientific symposium on all things #neoadjuvant.

Subscribe here: https://t.co/B8fv2qZZrv

@UZLeuven @KU_Leuven @LKILeuven @oncodaily

[Gertjan Rasschaert @GJRas]

First patient dosed worldwide today in #AZUR4 at @UZLeuven 🌎🏅

While the exact relevance of #pCR as a surrogate endpoint remains an important question for debate, still, very curious where we will land. Time will tell. ⏰🤔

#pMMR #MSS #CRC @LKILeuven

[Gertjan Rasschaert @GJRas]

#CRC highlights from @ASCO #GI25:
#8HW, #breakwater, #alascca, #bespoke, #botbal metastatic and neoadjuvant, @Agenus_Bio, etc.

Bridging towards our now open #AZUR4 @GSK neoadjuvant trial in #pMMR #MSS CRC at @UZLeuven

[MediMix @Medi_Mix]

🚨Highlights from #ASCOGI2025! Dr @GJRas unveils key advances in colorectal cancer. From immunotherapy breakthroughs to predictive biomarkers and preventive strategies, catch all the latest insights.

[Gertjan Rasschaert @GJRas]

Next time, I need some ‘fond de teint’ to cover up the jet lag marks 🥲

[MediMix @Medi_Mix]

🚨Poster from #ASCOGI2025! Dr @GJRas presents a novel IS-IC model to predict ICB response in mCRC.
🔹 High-score groups show ICB-sensitive stroma.
🔹 Multiplex immunofluorescence confirms biomarker validity.

[Gertjan Rasschaert @GJRas]

Immunosensitivity cuts across mismatch repair status in colorectal cancer

Our preview article on the recent Acha-Sagredo et al. has been published today in @Cancer_Cell.

https://t.co/FGK8lgHQJ7

[Jenny Seligmann @JenSeligmann]

🎆 Now online - my 2 fav topics in one paper
👍FOxTROT Ph2 FOLFOX+/- pani in locally advanced RAS/RAF-wt colon cancer
👍Convincing activity of anti-EGFR on long term outcomes, esp in hyperselected pts
❓Time to re-think targeted agents in LACC/LARC

https://t.co/wDhAkgCYw5

[Gertjan Rasschaert @GJRas]

👇

[Dr. Marwan G. Fakih @mgfakih]

We have compared the performance ctDNA by Natera vs. imaging in curatively resected colorectal cancer on surveillance. Signatera missed 31% of recurrences (+ imaging and negative Signatera). Largest study of comparative strategies. https://t.co/slg6r2Qvsm

[Gertjan Rasschaert @GJRas]

@UZLeuven @azoostende @mdl_azdelta @AZMMGent #AZorg @imeldabonheiden @ClinUnivStLuc #CHCLiège @CHULiege @JulesBordet

[Gertjan Rasschaert @GJRas]

Exciting times ahead! Happy to see our passion project getting off the ground. Let’s explore immuneresponsiveness in the NA setting for pMMR/MSS CRC.

Next to a couple top sites in UK, Spain & Swiss, AZUR-4 will especially run at our Belgian NA platform with 10 partners in crime!

[Gertjan Rasschaert @GJRas]

🔪Salvage surgery for unifocal progressive metastatic dMMR GI cancer responding to #ICI

https://t.co/S2TpFNnZRr

Interesting new article in @JCOPO_ASCO from our @UZLeuven / @KU_Leuven team. 💪

@JDekervel, @FilipHerpe, @iBakiTopal, @deroose_c, @decaesteckerj, @WolthuisA et al.

[Gertjan Rasschaert @GJRas]

👆🏽Save the date: 05-06 December, Towards New Standards in Colorectal Cancer.

✍️ Registration:
https://t.co/QqFshKJzWK

👥👥 @UZLeuven CRC MDT:
@DhooreAndre, Sabine Tejpar, @WolthuisA, @JDekervel, @jaekersj, @FilipHerpe, @GJRas, @bisle84, et al.

[Gertjan Rasschaert @GJRas]

@disconaivete @pitchfork Iceage has 5 out of 5

[Gertjan Rasschaert @GJRas]

Ready for #ESMO24 in Barcelona 🦭

[Bram Verstockt @bverstockt]

Where innovation crosses boundaries! Final countdown has started! If you haven’t registered yet, register today! Looking forward welcoming you soon in Leuven for our International Congress! @ibdleuven @SeverineVermei1 @JoaoPGSabino @DhooreAndre @bisle84

https://t.co/1h2859p3cM

[Gertjan Rasschaert @GJRas]

2/2 However still real-world study... Hetererogenous small population (N= 22) both dMMR/MSI & pMMR/MSS tumors. Not clear who received ICB only, who received combination with chemotherapy.

Future prospective studies are coming!

@Cancer_Cell @CellCellPress @PKU1898

[Gertjan Rasschaert @GJRas]

1/2 Very interesting work by Zemin Zhang and esteemed colleagues tracking immune dynamics of #CRC patients under PD-1 blockade.

https://t.co/SYgigqxvUc